IP Library Granted Patent US 7,507,196
Granted Patent B2
US 7,507,196 · App. 11/433,840 · Granted Mar 24, 2009

Antisense antiviral compounds and methods for treating a filovirus infection

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,507,196
App. No.
11/433,840
Granted
Mar 24, 2009
Kind
B2
Abstract

The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Filoviridae family, and in the treatment of a viral infection. The compounds and methods relate to the treatment of viral infections in mammals including primates by Ebola and Marburg viruses. The antisense antiviral compounds are morpholino oligonucleotides having: a) a nuclease resistant backbone, b) 15-40 nucleotide bases, and c) a targeting sequence of at least 15 bases in length that hybridizes to a target region selected from the following: i) the AUG start site region of VP35, as exemplified by SEQ ID NOS:67-71 or ii) the AUG start site region of VP24, as exemplified by SEQ ID NOS:72-76.

Claims (13)

1. A method of treating Filovirus infection in a subject, comprising:

administering to a subject a therapeutically effective amount of an antiviral composition of an antisense oligomer, wherein the oligomer comprises:

morpholino subunits linked by phosphorous-containing intersubunit linkages which join a morpholino nitrogen of one subunit to a 5′ exocyclic carbon of an adjacent subunit, wherein at least 2 and no more than half of the total number of intersubunit linkages are positively charged at physiological pH; and

a targeting sequence which forms a heteroduplex with a target sequence of the AUG start-site region of a positive-strand mRNA for Filovirus viral protein 35 (VP35);

wherein the antisense oligomer inhibits virus production.

2. The method of claim 1 , wherein the targeting sequence forms a heteroduplex with the AUG start-site region defined by SEQ ID NO:1.

3. The method of claim 2 , wherein the targeting sequence is complementary to at least 12 contiguous bases of the sequence of SEQ ID NO:1.

4. The method of claim 2 , wherein the oligomer has between 12-40 subunits.

5. The method of claim 2 , wherein the heteroduplex has a Tm of dissociation of at least 45° C.

6. The method of any one of claims 1 to 5 , wherein the morpholino subunits are joined by intersubunit linkages in accordance with the structure:

wherein Y 1 ═O, Z=O, Pj is a purine or pyrimidine base-pairing moiety effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide, and X is selected from alkyl alkoxy; thioalkoxy; —NR 2 , wherein each R is independently H or lower alkyl; or 1-piperizino.

7. The method of claim 1 , wherein the Filovirus is ebola virus.

8. The method of claim 7 , wherein the ebola virus is viral strain ebola Zaire.

Assignments (6)
CHANGE OF NAME Recorded May 30, 2019
From: AVI BIOPHARMA, INC.
To: SAREPTA THERAPEUTICS, INC.
Reel/Frame 049315/0774 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2011
From: IVERSEN, PATRICK L.
To: AVI BIOPHARMA, INC.
Reel/Frame 026594/0050 →
CHANGE OF NAME Recorded Jul 14, 2011
From: ANTIVIRALS, INC.
To: AVI BIOPHARMA, INC.
Reel/Frame 026594/0997 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2010
From: BAVARI, SINA
To: ARMY, UNITED STATES
Reel/Frame 025304/0922 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2009
From: BAVARI, SINA
To: UNITED STATES ARMY U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND
Reel/Frame 022384/0950 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 9, 2006
From: WELLER, DWIGHT D.
To: AVI BIOPHARMA, INC.
Reel/Frame 018080/0581 →